Related Experiment Videos
Effect of verapamil on atherosclerosis
G Leonetti1, L Sampieri, R Bragato
1Ospedale S. Luca, Centro Auxologico Italiano, Milan.
Drugs
|January 1, 1993
Summary
Verapamil, a calcium channel blocker, may prevent atherosclerosis independently of blood pressure reduction. Human studies show mixed results on its antiatherosclerotic effects, particularly after coronary angioplasty and in bypass surgery patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- The antiatherosclerotic effects of antihypertensive agents are debated, with uncertainty regarding whether benefits stem from blood pressure reduction or independent mechanisms.
- Animal studies suggest verapamil, a calcium antagonist, offers preventive rather than therapeutic antiatherosclerotic effects, independent of its blood pressure-lowering action, though at higher doses than used in humans.
Purpose of the Study:
- To investigate the antiatherosclerotic effects of verapamil, a calcium antagonist, in human studies.
- To clarify whether verapamil's potential antiatherosclerotic effects are independent of its blood pressure-lowering properties.
Main Methods:
- Review of existing human studies on verapamil's effects on restenosis after coronary angioplasty.
- Analysis of conflicting results from retrospective and prospective studies in patients with coronary stenosis undergoing bypass surgery.
- Consideration of ongoing research on verapamil's impact on carotid artery lesions in hypertensive patients.
Main Results:
- Verapamil appears to reduce restenosis rates following coronary angioplasty.
- Studies on verapamil's effect in patients with coronary stenosis undergoing bypass surgery have yielded conflicting outcomes.
- The precise relationship between blood pressure reduction and verapamil's impact on atherosclerotic lesions remains unclear.
Conclusions:
- Verapamil demonstrates potential in preventing restenosis post-coronary angioplasty.
- Further research, including ongoing studies on carotid arteries, is necessary to definitively establish verapamil's independent antiatherosclerotic role in hypertensive patients.